Callan Family Office LLC Purchases New Holdings in Takeda Pharmaceutical Co. $TAK

Callan Family Office LLC purchased a new stake in shares of Takeda Pharmaceutical Co. (NYSE:TAK) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 47,762 shares of the company’s stock, valued at approximately $738,000.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in TAK. FNY Investment Advisers LLC bought a new position in Takeda Pharmaceutical during the first quarter valued at about $37,000. Farther Finance Advisors LLC grew its stake in shares of Takeda Pharmaceutical by 29.2% in the 1st quarter. Farther Finance Advisors LLC now owns 4,620 shares of the company’s stock valued at $69,000 after purchasing an additional 1,045 shares during the period. Fifth Third Bancorp grew its stake in shares of Takeda Pharmaceutical by 85.5% in the 1st quarter. Fifth Third Bancorp now owns 5,232 shares of the company’s stock valued at $78,000 after purchasing an additional 2,411 shares during the period. GAMMA Investing LLC grew its stake in shares of Takeda Pharmaceutical by 22.6% in the 1st quarter. GAMMA Investing LLC now owns 7,042 shares of the company’s stock valued at $105,000 after purchasing an additional 1,296 shares during the period. Finally, Caitong International Asset Management Co. Ltd bought a new stake in shares of Takeda Pharmaceutical in the 1st quarter valued at approximately $125,000. 9.17% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on TAK. Zacks Research lowered Takeda Pharmaceutical from a “hold” rating to a “strong sell” rating in a research note on Thursday, August 21st. Weiss Ratings reiterated a “hold (c)” rating on shares of Takeda Pharmaceutical in a research note on Saturday, September 27th. One equities research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold”.

Takeda Pharmaceutical Stock Up 0.0%

NYSE TAK opened at $13.72 on Tuesday. The firm has a market cap of $43.64 billion, a PE ratio of 45.72 and a beta of 0.21. Takeda Pharmaceutical Co. has a one year low of $12.80 and a one year high of $15.69. The stock’s 50 day simple moving average is $14.85 and its 200 day simple moving average is $14.78. The company has a debt-to-equity ratio of 0.60, a current ratio of 1.16 and a quick ratio of 0.59.

Takeda Pharmaceutical (NYSE:TAK) last released its quarterly earnings results on Wednesday, July 30th. The company reported $0.52 EPS for the quarter, topping analysts’ consensus estimates of $0.47 by $0.05. The business had revenue of $7.45 billion for the quarter, compared to analyst estimates of $7.96 billion. Takeda Pharmaceutical had a return on equity of 10.50% and a net margin of 3.20%. Takeda Pharmaceutical has set its FY 2025 guidance at 3.360-3.360 EPS. As a group, sell-side analysts forecast that Takeda Pharmaceutical Co. will post 1.64 earnings per share for the current fiscal year.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.